BACKGROUND: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. PATIENTS AND METHODS: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus >or= 1 day of FN)]. RESULTS: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2-8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface <or= 2 m(2), a baseline monocyte count <150/microl and the interaction between the first cycle in the same treatment line and a baseline hemoglobin dosage. A rule of prediction of FN was computed with these characteristics: sensitivity 78.6%, specificity 62.3%, positive predictive value 42.7% and negative predictive value 89.1%. CONCLUSION: Further studies are needed to validate this score.
BACKGROUND: Chemotherapy-induced neutropenia is the most common adverse effect of chemotherapy and is often complicated by febrile neutropenia (FN). The objective of this study is to validate a classification of aggressiveness of a chemotherapy regimen and to evaluate its usefulness in a risk prediction model of FN in patients with hematological cancer at the beginning of a chemotherapy cycle. PATIENTS AND METHODS: Two hundred and sixty-six patients were prospectively enrolled and followed during 1053 cycles. Relevant patient informations were collected at the beginning of the first cycle and the number of days of FN were counted in the follow-up [dichotomized (no FN versus >or= 1 day of FN)]. RESULTS: Aggressive chemotherapy regimen is the major predictor of FN [odds ratio 5.2 (3.2-8.4)]. The other independent predictors are the underlying disease, an involvement of bone marrow, body surface <or= 2 m(2), a baseline monocyte count <150/microl and the interaction between the first cycle in the same treatment line and a baseline hemoglobin dosage. A rule of prediction of FN was computed with these characteristics: sensitivity 78.6%, specificity 62.3%, positive predictive value 42.7% and negative predictive value 89.1%. CONCLUSION: Further studies are needed to validate this score.
Authors: Maristela P Freire; Ligia C Pierrotti; Antonio E Zerati; Luciana Benites; Joaquim Mauricio da Motta-Leal Filho; Karim Y Ibrahim; Pedro H Araujo; Edson Abdala Journal: Antimicrob Agents Chemother Date: 2018-08-27 Impact factor: 5.191
Authors: Gary H Lyman; Nicole M Kuderer; Jeffrey Crawford; Debra A Wolff; Eva Culakova; Marek S Poniewierski; David C Dale Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: Kristian Hastoft Jensen; Ivan Vogelius; Claus Ernst Moser; Elo Andersen; Jesper Grau Eriksen; Jørgen Johansen; Mohammad Farhadi; Maria Andersen; Jens Overgaard; Jeppe Friborg Journal: Br J Cancer Date: 2021-05-20 Impact factor: 7.640